Evidence map›Paper›PMID 34316329›Full record

ArticleOncotarget2021

The impact of neoadjuvant concurrent chemoradiation on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma.

Moh'd Khushman, Pranitha Prodduturvar, Wadad Mneimneh, Valeria Dal Zotto, Shalla Akbar, Leander Grimm, Paul Rider, John Hunter, Omar Alkharabsheh, Girijesh Kumar Patel and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Moh'd KhushmanHematology-Oncology, O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, AL, USA.
Pranitha ProdduturvarMedical Oncology, Mayo Clinic, Rochester, MN, USA.
Wadad MneimnehPathology, Case Western Reserve University, Cleveland, OH, USA.
Valeria Dal ZottoPathology, The University of South Alabama, Mobile, AL, USA.
Shalla AkbarPathology, The University of South Alabama, Mobile, AL, USA.
Leander GrimmColorectal Surgery, The University of South Alabama, Mobile, AL, USA.
Paul RiderColorectal Surgery, The University of South Alabama, Mobile, AL, USA.
John HunterColorectal Surgery, The University of South Alabama, Mobile, AL, USA.
Omar AlkharabshehHematology-Oncology, O'Neal Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, AL, USA.
Girijesh Kumar PatelDepartment of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, TX, USA.
Jesus C FabregasHarvard T.H. Chan School of Public Health, Boston, MA, USA.
Ajay P SinghPathology, The University of South Alabama, Mobile, AL, USA.
University of South Alabama · USUniversity of Alabama at Birmingham · USCase Western Reserve University · USHarvard University · USMayo Clinic in Arizona · USTexas Tech University Health Sciences Center · US

Funding

A novel molecular cross-talk driving pancreatic cancer progressionR01CA224306 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2018 to 2022
$1.7M
NCI NIH HHS R01 CA224306
6 · The paper itself

Abstract

introductionExosomes have pivotal roles in cancer development. The impact of neoadjuvant concurrent chemoradiation (NCCR) on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma are yet to be explored. MATERIALS AND

methodsBetween 2015 and 2018, 33 patients had rectal adenocarcinoma treated with NCCR and had pre-NCCR biopsy and post-NCCR resected rectum. CD63 and CD9 expression was assessed by immunohistochemistry (IHC). The short-term surrogate endpoint neoadjuvant rectal (NAR) score was used for assessment of prognostic significance. Un-Paired

resultsThe mean tumor CD63 and CD9 scores in pre-NCCR biopsy vs. post-NCCR resected rectum were 106 vs. 165 (

conclusionsThe expression of the exosomal markers (CD63 and CD9) increased in patients with rectal adenocarcinoma after treatment with NCCR. The exosomal markers (CD63 and CD9) may have a prognostic significance. There was a trend for higher CD63 and CD9 expression in patients with high NAR score compared with low-intermediate NAR scores. The lack of statistical significance is likely due to the small sample size.

Indexed as

CD63CD9exosomal markersexosomesneoadjuvant chemoradiation

Identifiers

PMID34316329
PMCPMC8310674
OpenAlexW3179207373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.